Skip to main content
OpenTrials
Completed

NCT Number: NCT05214755

Translation, Cross-Cultural Adaptation and Turkish Validation of the 25-Question Geriatric Locomotive Function Scale

25-question Geriatric Locomotive Function Scale (GLFS-25) is a patient-reported outcome measure consisting of 25 questions that evaluates locomotive functions and locomotive syndrome risk in elderly individuals.

The purpose of this study was to translate and cross-culturally adapt the English version of the GLFS-25 into Turkish and to investigate the reliability and validity of the translated version of the scale.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Istanbul University-Cerrrahpasa

Istanbul, Turkey (Türkiye)

About this study

Aging is an inevitable process that begins after birth and continues until the death of the individual, affecting the person mentally and physically. Approximately 21% of elderly individuals requiring care have locomotive organ disorders involving the bone, joint, muscle and nervous system. 25-question Geriatric Locomotive Function Scale (GLFS-25), developed by Japanese researchers in 2012, is a patient-reported outcome measure consisting of 25 questions that evaluates locomotive functions and locomotive syndrome risk in elderly individuals. This scale provides an advantage in terms of locomotive ability and early detection of locomotive syndrome in the elderly. In addition, the scale provides the opportunity to decrease number of needing for hospital care of elderly individuals by early detection of locomotive functions and the risk of locomotive syndrome. Before a patient-reported outcome measure can be used in a society other than the one in which it was developed, it must be translated and culturally adapted. The GLFS-25 have been translated to different cultural settings and into many languages, including Brazilian, Iranian and Chinese. Data obtained from the culturally adapted versions contribute to a better understanding of the tools measurement properties. The studies reported that translated versions of GLFS-25 reliable and valid in older adults for functional assessment. Therefore, a Turkish version of the GLFS-25 would likely be that would be helpful in the functional state management and risk factor analyzes for locomotive syndrome of the Turkish older adult population. The purpose of this study was to translate and cross-culturally adapt the English version of the GLFS-25 into Turkish and to investigate the reliability and validity of the translated version of the scale.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • over the age of 65
  • who can answer the questionnaire on their own or with the help of their relatives

Exclusion criteria

  • unable to walk without the assistance of another person
  • having a brain disease or severe cardiovascular, pulmonary or renal disease
  • having a history of lower extremity and/or spine fractures in the last 6 months
  • were treated for acute trauma

Treatment and study plan

Primary outcomes

  1. 25-question Geriatric Locomotive Function Scale (GLFS-25)

    Time frame: Baseline

    GLFS-25 is an assessment tool developed for evaluate locomotive functions in elderly individuals. This scale consists of a self-reported questionnaire with 25 items that are easily understood by the elderly, and each item is graded from 0 to 4 points. The final score is determined by the sum of all items ranging from 0 to 100.

Secondary outcomes

  1. 25-question Geriatric Locomotive Function Scale (GLFS-25)

    Time frame: Within a 7-to-14-day period after the first assessment

    GLFS-25 is an assessment tool developed for evaluate locomotive functions in elderly individuals. This scale consists of a self-reported questionnaire with 25 items that are easily understood by the elderly, and each item is graded from 0 to 4 points. The final score is determined by the sum of all items ranging from 0 to 100.

  2. Katz Index

    Time frame: Baseline

    The scale consists of 6 questions evaluating washing, dressing, toilet, continence, transfer and feeding activities. For activities, 'dependent' is evaluated with 0 point and 'independent' is evaluated with 1 point. Six points indicate complete independence, 0 point complete dependence.

  3. Lawton Index

    Time frame: Baseline

    This index includes 8 activities: the ability to use a phone, shopping, using public transport, meal preparation, doing daily housework, traveling, the responsibility for using medication and the ability to handle finance. The scoring scale is 0 and 1, and the sum of the scores is varied from 0 to 8 points.

  4. Visual Analogue Scale (VAS)

    Time frame: Baseline

    The VAS assesses pain status on a 10 cm chart, with 0 points defined as "no pain" and 10 points as "terrible pain".

  5. Geriatric Depression Scale

    Time frame: Baseline

    Geriatric Depression Scale is a 30-item scale that evaluates the level of depression in elderly individuals. Questions 1,5,7,9,15,19,21,28,29 and 30 in the scale are evaluated with 0 point for 'yes' and 1 point for 'no'. The total scoring is 30 points, and individuals who score 14 are reported to have a high risk of depression.

Sponsors and collaborators

Lead sponsor

Istanbul Aydın University

Other

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Jan 31, 2022
Registry last updated
Aug 3, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.